Attached files

file filename
EX-31.2 - CERTIFICATION - Cellular Biomedicine Group, Inc.cmbg_ex312.htm
EX-31.1 - CERTIFICATION - Cellular Biomedicine Group, Inc.cmbg_ex311.htm
EX-32.1 - CERTIFICATION - Cellular Biomedicine Group, Inc.cmbg_ex321.htm
EX-10.11 - AMENDED AND RESTATED 2011 INCENTIVE STOCK OPTION PLAN - Cellular Biomedicine Group, Inc.cmbg_ex1011.htm
EXCEL - IDEA: XBRL DOCUMENT - Cellular Biomedicine Group, Inc.Financial_Report.xls
10-Q - QUARTERLY REPORT - Cellular Biomedicine Group, Inc.cmbg_10q.htm
Exhibit 99.1
 
Supplemental Pro-Forma Income Statement
 
                                     
   
Three Months Ended March 31, 2013
   
Three Months Ended March 31, 2012
 
   
CBMG
   
EastBridge
   
Pro-forma
   
CBMG
   
EastBridge
   
Pro-forma
 
   
As stated
   
Q1 2013
   
Consolidated
   
As stated
    Q1 2012    
Consolidated
 
Revenues
  $ -     $ -     $ -     $ 78,589     $ -     $ 78,589  
                                                 
Cost of goods sold
    -       -       -       27,690       -       27,690  
                                                 
Gross profit
    -       -       -       50,899       -       50,899  
                                                 
Operating expenses:
                                               
General and administrative
    5,071,917       212,770       5,284,687       696,511       212,831       909,342  
Selling and marketing
    28,701       18,392       47,093       29,721       13,464       43,185  
Research and development
    480,505       -       480,505       255,954       -       255,954  
         Total operating expenses
    5,581,123       231,162       5,812,285       982,186       226,295       1,208,481  
Operating loss
    (5,581,123 )     (231,162 )     (5,812,285 )     (931,287 )     (226,295 )     (1,157,582 )
                                                 
Other income (expense)
                                               
Interest expense
    (257,438 )     -       (257,438 )     -       1,675       1,675  
Interest income
    971       455       1,426       1,013       -       1,013  
Gain on extinguishment of debt
    -       -       -       -       6,128       6,128  
Other expense
    (6,071 )     -       (6,071 )     -       (25,883 )     (25,883 )
        Total other income (expense)
    (262,538 )     455       (262,083 )     1,013       (18,080 )     (17,067 )
Loss before taxes
    (5,843,661 )     (230,707 )     (6,074,368 )     (930,274 )     (244,375 )     (1,174,649 )
                                                 
Income tax provision
    -       -       -       -       -       -  
Net loss
  $ (5,843,661 )   $ (230,707 )   $ (6,074,368 )   $ (930,274 )   $ (244,375 )   $ (1,174,649 )
Other comprehensive income (loss):
                                               
Cumulative translation adjustment
    (1,960 )     -       (1,960 )   $ 5,819       -       5,819  
Unrecognized loss on investments
    (620,880 )     (4,047,912 )     (4,668,791 )     -       (22,847 )     (22,847 )
Comprehensive net loss
  $ (6,466,501 )   $ (4,278,619 )   $ (10,745,119 )   $ (924,455 )   $ (267,222 )   $ (1,191,677 )
                                                 
Earnings per share:
                                               
  Basic and diluted
  $ (1.25 )   $ (0.54 )   $ (1.30 )   $ (0.32 )   $ (0.16 )   $ (0.27 )
                                                 
Weighted average common shares outstanding:
                                         
  Basic and diluted
    4,668,283       429,009       4,668,283       2,877,825       1,548,917       4,426,742